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Introduction
Several prognostic factors related to patients' and disease characteristics have been described for acute myeloid leukemia (AML). 1, 2 The karyotype at diagnosis is a powerful prognostic factor for treatment outcome in patients with AML. [3] [4] [5] [6] [7] Various recurrent somatically acquired molecular abnormalities have been identified during the last years. 8 Of these molecular abnormalities, mutations in nucleophosmin (NPM1) and internal tandem duplications of the fms-related tyrosine kinase 3 gene (FLT3-ITD) have strong prognostic impact.
Mutations in NPM1 are the most frequently observed molecular abnormalities, present in about 50% of AML cases, and are associated with a favorable outcome. [9] [10] [11] [12] [13] AML with mutated NPM1 (NPMc + ) shows distinctive biological and clinical features, and is, therefore, a provisional entity in the World Health Organization (WHO) 2008 classification of leukemias. FLT3-ITD is another frequent molecular abnormality and can be observed in about 20-25% of patients with AML. [14] [15] [16] [17] [18] Clinically, AML patients harboring FLT3-ITD frequently have high white blood cell (WBC) counts at presentation. [14] [15] [16] [17] [18] The presence of FLT3-ITD is generally considered as an unfavorable prognostic factor. [14] [15] [16] [17] [18] [19] In particular, those cases with a FLT3-ITD mutation/FLT3 wild-type ratio (hereafter referred to as the FLT3-ITD/FLT3 ratio) above the median value have a dismal prognosis. [17] [18] [19] A high FLT3-ITD/FLT3 ratio points to the absence of the FLT3 wild-type allele.
Mutations in NPM1 and FLT3-ITD are frequently associated. Approximately 40% of patients with NPM1 mutations also carry FLT3-ITD. 9 Various studies have shown that the genotypic combination 'NPMc + without FLT3-ITD' represents a subgroup with favorable prognosis. [9] [10] [11] [12] [13] Nevertheless, the beneficial impact of NPMc + on prognosis was seen in patients with as well as those without FLT3-ITD and it appeared that both mutations in NPM1 and FLT3-ITD were significant independent predictors of outcome. 19 Besides cytogenetic and molecular abnormalities, classically, a high WBC count at presentation is considered to be an independent prognostic factor for poor outcome in both adults and children with AML. 1, [20] [21] [22] [23] The effect of WBC count at diagnosis is most apparent in AML with favorable cytogenetic risk abnormalities, such as t (8;21) and t (15;17) . [24] [25] However, the prognostic effect of WBC count is also present in AML patients with intermediate cytogenetic risk abnormalities. [20] [21] [22] [23] Multivariable analysis has shown that both WBC count and the genotypic subgroup NPMc + without FLT3-ITD are independent predictors of outcome. 11 Nevertheless, the effect of WBC count at diagnosis on outcome of patients within the four subgroups defined by the molecular markers NPMc + and FLT3-ITD (within the intermediate cytogenetic risk group) is unknown.
The aim of the present survey was to investigate the prognostic impact of WBC count at diagnosis on outcome within AML subgroups defined by NPMc + and FLT3-ITD or the FLT3-ITD/FLT3 ratio. Therefore, within a clinically and molecularly well characterized cohort of 525 patients with de novo AML, we compared treatment outcome among patients divided into three groups on the basis of their WBC counts: less than 20¥10 9 /L, 20 to 100¥10 9 /L, and above 100¥10 9 /L.
Design and Methods

Patients
The study cohort consisted of 525 consecutive adult patients with AML who were treated according to the sequential HOVON/SAKK AML-04, -04A, -29, -32, -42, -43 protocols (available at http://www.hovon.nl) and for whom molecular data on NPMc + and FLT3-ITD status were available. [26] [27] [28] [29] All patients in this study were newly diagnosed with AML and the diagnosis was established according to WHO criteria. Cell specimens were collected at the time of diagnosis. All patients provided written informed consent in accordance with the Declaration of Helsinki, and the study was approved by all participating institutional review boards. Patients were divided into cytogenetic risk groups (favorable, intermediate, or unfavorable) in accordance with HOVON/SAKK criteria (Table 1) . Cytogenetic risk was defined as favorable in patients with t(8;21)(q22;q22), inv(16)(p13.1;q22), or t(16;16)(p13.1;q22) and t (15;17) , and unfavorable in patients with complex cytogenetic abnormalities (i.e. three or more distinct clonal abnormalities), -7, -5, del 5q or del 7q, abnormalities of the long arm of chromosome 3 (abn 3q), t(6;9)(q23;q34), t(9;22)(q34;q11), or abnormalities of the long arm of chromosome 11 (abn 11q23). All other cytogenetic abnormalities and AML without cytogenetic abnormalities were considered to indicate an intermediate cytogenetic risk. The median overall survival of the whole cohort was 16.3 months, and the median follow-up of survivors was 61.4 months.
Guided by thresholds of WBC counts which are often clinically used for risk stratification, the 525 patients were divided into three groups: those with a WBC count below 20¥10 
FLT3-ITD/FLT3-wildtype ratio
Amplification of the FLT3-ITD mutations was performed using primers 11F and 11R, as described by Nakao et al. 30 Ratios were determined after agarose gel electrophoresis of the quantitative polymerase chain reaction products.
Statistical analyses
Statistical analyses were performed with SPSS software, release 16.0. Actuarial probabilities of overall survival (with death due to any cause) as well as event-free survival (with failure in case of no complete remission or relapse or death) were estimated according to the Kaplan-Meier method. For quantitative parameters overall differences between the cohorts were evaluated using an F-test (or Student's-t test in the case of two groups) for normally distributed variables or a Kruskal-Wallis test (or Mann-Whitney-U test in the case of two groups) for variables with a skewed distribution. For qualitative parameters, overall group differences were evaluated using a χ 2 test. Cox regression analysis was applied to determine the association of WBC and overall and event-free survivals with 
Results
Patients
The clinicopathological, demographic, and molecular data of the 525 patients with AML in the study cohort are presented in Table 1 . Guided by thresholds of WBC counts which are often clinically used for risk stratification, the 525 patients were divided into three groups: those with a WBC count below 20¥10 9 /L (n=221), those with a WBC count between 20 and 100¥10 9 /L (n=205) and those with a WBC above 100¥10 9 /L (n=99). Impact of white blood cell count on complete remission rate, event-free survival and overall survival When considering all 525 patients, hyperleukocytosis was significantly associated with a lower complete remission rate (67% versus 84%; P<0.001), shorter event-free survival (median 6.8 months versus 11.6 months; P=0.001) and shorter overall survival (median 8.9 months versus 17.2 months; P=0.002) (Online Supplementary Figure S1A, Since we aimed to investigate the impact of WBC count on outcome within the four subgroups defined by the molecular markers NPMc + and FLT3-ITD (within the intermediate cytogenetic risk group), we subsequently focused on these subgroups. In the most favorable genotypic subgroup, 'NPMc + without FLT3-ITD', WBC count did not significantly affect complete remission rate (P=0.451), event-free survival (P=0.932) or overall survival (P=0.400) ( Figure 1A,B) . Furthermore, also when WBC count was analyzed as a continuous variable, no significant association was found between WBC count and event-free and overall survival in the subgroup 'NPMc + without FLT3-ITD' (data not shown). Interestingly, however, in the subgroup with the genotypic combination 'NPMc + with FLT3-ITD' WBC count did have a significant impact on complete remission rate (P=0.034), event-free survival (P=0.009) and overall survival (P<0.001) (Figure 1C,D) . Within this particular subgroup, it appeared that patients with a WBC count less than 20¥10 9 /L or between 20-100¥10 9 /L had a relatively favorable prognosis with a median overall survival of 21 and 15 months, respectively, and estimated 5-year overall survival rates of 50% and 51%, respectively. In contrast, patients with a WBC greater than 100¥10 9 /L evidently had a poor prognosis with a median overall survival of 7 months and an estimated 5-year overall survival rate of 9%. So, based on WBC count (i.e. <100 versus >100¥10 9 /L) patients with the genotypic combination 'NPMc + with FLT3-ITD' could be divided into two groups, one with a relatively good prognosis, the other with a very poor prognosis. These results were underscored by univariate Cox regression analyses using WBC count as a continuous variable for event-free survival 
P<0.001).
In the two other subgroups 'NPM1 wild-type with FLT3-ITD' and 'NPM1 wild-type without FLT3-ITD', WBC count had no evident impact on complete remission rate, event-free survival or overall survival ( Figure 1E-H combination 'NPMc + with FLT3-ITD' depending on whether they had a high or low WBC count. To address this question, we investigated the impact of the FLT3-ITD/FLT3 ratio on clinical outcomes within this particular subgroup of patients. The FLT3-ITD/FLT3 ratio was known for all 75 patients and was categorized as less than 1, 1, or more than 1. Interestingly, the FLT3-ITD/FLT3 ratio was significantly associated with event-free survival (P=0.001) and overall survival (P=0.001) within this subgroup of patients (Figure 2) . In detail, patients with an FLT3-ITD/FLT3 ratio greater than 1 had a significantly shorter event-free survival (median 5.6 months versus 15.2 and 13.0 months for patients with a ratio of 1 and <1, respectively) as well as a significantly shorter overall survival (median 7.7 months versus 16.5 and 31.3 months for patients with a ratio of 1 and <1, respectively). Thus, it appears that particularly patients with the genotypic combination 'NPMc + with FLT3-ITD' and an FLT3-ITD/FLT3 ratio greater than 1 had a poor outcome.
So far, our data indicate that the group of patients with intermediate cytogenetic risk AML with the genotypic combination 'NPMc + with FLT3-ITD' can be further dissected, with the subgroup of patients with hyperleukocytosis or FLT3 ITD/FLT3 ratio greater than 1 having an unfavorable prognosis. However, interestingly, not all patients with hyperleukocytosis had an FLT3-ITD/FLT3 ratio greater than 1 and vice versa (Table 3A) . To investigate whether a FLT3-ITD/FLT3 ratio greater than 1 and hyperleukocytosis are indeed independent prognostic factors for patients with AML with the genotypic combination 'NPMc + with FLT3-ITD', a multivariable analysis was performed. This analysis established that FLT3-ITD/FLT3 ratio greater than 1, WBC count greater than 100¥10 9 /L and age are independent prognostic factors. In detail, with regards to FLT3-ITD/FLT3 ratio greater than 1, the hazard ratio for event-free survival was 2.84 (P<001) while that for overall survival was 3.19 (P<0.001); for hyperleukocytosis the hazard ratio for event-free survival was 2.29 (P=0.004) and for overall survival 3.30 (P<0.001), and finally, for age (in decades), the hazard ratio for event-free survival was 2.13 (P=0.017) and that for overall survival was 1.35 (P=0.011) (Table 3B) .
These data prompted us to propose a model in which patients with intermediate cytogenetic risk AML with the genotypic combination 'NPMc + with FLT3-ITD' were considered to have an unfavorable prognosis if they had a WBC count greater than 100¥10 9 /L or an FLT3-ITD/FLT3 ratio greater than 1. Consequently, patients with a WBC count below 100¥10 ( Figure 3) . In detail, patients with a WBC count below 100¥10 9 /L and an FLT3-ITD/FLT3 ratio of 1 or less had median event-free and overall survivals of 24 and 33 months, and estimated 5-year event-free and overall survival rates of 71% and 79%, respectively. In contrast, patients with hyperleukocytosis or an FLT3-ITD/FLT3 ratio greater than 1 had median event-free and overall survivals of 7 and 8 months, and estimated 5-year event-free and overall survival rates of 16% and 18%, respectively. Of note, the median age at diagnosis and the number of patients who had undergone allogeneic stem cell transplantation was not different between these two groups (P=0.55 and P=0.17, respectively).
Discussion
It is generally accepted, and confirmed in this study, that high WBC count predicts an adverse outcome among AML patients with favorable or intermediate cytogenetic risk. 1, 2, [20] [21] [22] [23] In the current study, we have focused on the impact of WBC count at diagnosis on outcome among patients with intermediate cytogenetic risk, divided into subgroups according to the presence of the molecular markers NPMc + and FLT3-ITD. It was found that the WBC count had an impact on complete remission rate, eventfree survival and overall survival only among the patients with the genotypic combination 'NPMc + with FLT3-ITD'. Importantly, these results were underscored when using WBC count as a continuous variable. Apparently, the impact of WBC count at diagnosis on treatment outcome is dependent on the molecular genotype of AML blasts since the poor prognostic impact of high WBC count can be bypassed by intrinsic molecular abnormalities of the AML blasts, such as mutated NPM1. This is consistent with observations that NPMc + AML blasts, independently of FLT3-ITD, have good response to chemotherapy in vivo and in vitro. 19, [31] [32] [33] Analysis of a large cohort of young adult AML patients by the MRC study-group showed that both mutations in NPM1 and FLT3-ITD are significant independent predictors of outcome, implying that the beneficial impact of NPMc + on prognosis is also seen in patients with FLT3-ITD. 19 A number of studies suggested that patients with AML harboring FLT3-ITD have a worse outcome than patients without FLT3-ITD. [14] [15] [16] [17] [18] However, the number of mutated alleles, rather than its presence or the insertion site of the ITD, has been shown to affect outcome. [17] [18] [19] 34, 35 Likewise, in our study we also found that patients with the genotypic combination 'NPMc + with FLT3-ITD' and high levels of the mutant allele (i.e. an FLT3-ITD/FLT3 ratio >1) had significantly worse long-term outcome. It is likely that higher levels of FLT3-ITD might trigger pathways involved in chemoresistance more intensively, for example by enhancing DNA repair and salvage of damaged cells. 36 Our observations confirm the importance of the FLT3-ITD/FLT3 ratio, representing the FLT3-ITD allelic burden, with regards to prognosis and demonstrate that WBC count is not a surrogate marker for the FLT3-ITD/FLT3 ratio, but indeed is an independent prognostic factor.
The importance of the WBC count and FLT3-ITD/FLT3 ratio as prognostic factors in AML patients with the genotypic combination 'NPMc + with FLT3-ITD' needs to be confirmed in further cohorts of patients. However, for the future it will be of interest to study whether patients with the genotypic combination 'NPMc + with FLT3-ITD' and low WBC count and an FLT3-ITD/FLT3 ratio less than 1 can be excluded from consolidation therapy with allogeneic hematopoietic cell transplantation. This would extend the work of Schlenk et al., 13 who demonstrated that patients with cytogenetically normal karyotype AML bearing the genotypic combination 'NPMc + without FLT3-ITD' had no survival benefit from allogeneic hematopoietic cell transplantation, with an overall survival of 50-60%.
In conclusion, the present study demonstrates that high WBC count and FLT3-ITD/FLT3 ratio are important prognostic factors in patients with AML with the genotypic combination 'NPMc + with FLT3-ITD'. 
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